Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use

Allergy and Asthma Proceedings

Volumn 36, Issue 4, 2015, Pages 268-274

  Zazzali, James L ^a   Broder, Michael S ^b   Omachi, Theodore A ^a   Chang, Eunice ^b   Sun, Gordon H ^b   Raimundo, Karina ^a  

^a GENENTECH INC   (United States)

^b PARTNERSHIP FOR HEALTH ANALYTIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; STEROID; ANTIASTHMATIC AGENT;

ADULT; AGE; ARTICLE; ASTHMA; BONE DISEASE; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DRUG EXPOSURE; DRUG USE; FEMALE; FRACTURE; GENDER; GEOGRAPHY; GLAUCOMA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PEPTIC ULCER; PNEUMONIA; RISK ASSESSMENT; STEROID THERAPY; ADOLESCENT; AGED; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTI-ASTHMATIC AGENTS; ASTHMA; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK; UNITED STATES; YOUNG ADULT;

EID: 84938307596     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2015.36.3863     Document Type: Article

References (19)

1. National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda: National Heart, Lung, and Blood Institute (US); 2007 Aug. Available online at http://www.ncbi.nlm.nih.gov/books/NBK7232/; accessed May 14, 2014.
2. Manson SC, Brown RE, Cerulli A, and Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 103:975-994, 2009.
3. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 9:30, 2013.
4. van Staa TP, Leufkens HGM, and Cooper C. The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis. Osteoporos Int 13:777-787, 2002.
5. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data. Ann Rheum Dis 65:285-293, 2006.
6. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55:420-426, 2006.
7. Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: Frequency, risk factors and patient's opinion. Br J Dermatol 157:142-148, 2007.
8. Schatz M, Broder M, Chang E, et al. Asthma quality-of-care measures using administrative data: Identifying the optimal denominator. Ann Allergy Asthma Immunol 102:98-102, 2009.
9. Zazzali JL, Raimundo K, Chang E, et al. Defining high oral corticosteroid use in asthma patients. American Thoracic Society International Meeting. San Diego, California, May 18, 2014.
10. Mullerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: A population database analysis. Respir Med 106:1124-1133, 2012.
11. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 187:728-735, 2013.
12. Chronic Condition Indicator (CCI) for ICD-9-CM. Summary and downloading information. Oct 2009. Agency for Health Care Policy and Research, Rockville, MD. Available online at http://www.hcup-us.ahrq.gov/toolssoftware/chronic/chronic. jsp; accessed May 14, 2014.
13. Berthold HK, Gouni-Berthold I, Böhm M, et al. Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovasc Diabetol 8:25, 2009.
14. Gulliford MC, Charlton J, and Latinovic R. Trends in antihypertensive and lipid-lowering therapy in subjects with type II diabetes: Clinical effectiveness or clinical discretion? J Hum Hypertens 19:111-117, 2005.
15. Zazzali JL, Broder M, and Chang E. Oral corticosteroid use increases the risk of glucocorticoid-related adverse events in asthmatics. American Academy of Allergy, Asthma, & Immunology Annual Meeting. San Diego, California, March 4, 2012.
16. Aubas C, Bourdin A, Aubas P, et al. Role of comorbid conditions in asthma hospitalizations in the south of France. Allergy 68:637-643, 2013.
17. Diette GB, Krishnan JA, Dominici F, et al. Asthma in older patients: Factors associated with hospitalization. Arch Intern Med 162:1123-1132, 2002.
18. McDonough AK, Curtis JR, and Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 20:131-137, 2008.
19. Wilper AP, Woolhandler S, Lasser KE, et al. A national study of chronic disease prevalence and access to care in uninsured U.S. adults. Ann Intern Med 149:170-176, 2008.